产品简要
公司名称 :
ACROBiosystems
产品类型 :
蛋白
产品名称 :
Human FGF R2 (IIIb) protein, His Tag (MALS verified)
目录 :
FGB-H5223
规格 :
1毫克, 100微克
价格 :
2310美元, 350美元
更多信息或购买 :
产品信息
公司名称 :
ACROBiosystems
产品类型 :
蛋白
目录 :
FGB-H5223
产品名称 :
Human FGF R2 (IIIb) protein, His Tag (MALS verified)
规格 :
1毫克, 100微克
价格 :
2310美元, 350美元
规格&价格 :
$350/100微克, $2310/1毫克
靶标 :
FGF R2(IIIb)
宿主物种 :
人类
By Tag :
多组氨酸标签
研究 :
For Research Use Only
来源 :
Human FGFR2 (IIIb), His Tag (FGB-H5223) is expressed from human 293 cells (HEK293). It contains AA Pro 154 - Leu 358 (Accession # P21802-3).
内毒素 :
Less than 1.0 EU per μg by the LAL method.
纯度 :
>90% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human FGFR2 (IIIb), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
配方 :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
重组 :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
储存 :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at: ● -20°C to -70°C for 12 months in lyophilized state; ● -70℃ for 3 months under sterile conditions after reconstitution.
背景 :
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.
参考文献 :
(1) Ornitz D.M. Xu J., et al. J. Biol. Chem. 271:15292-15297(1996). (2) Lu Y. Pan Z., et al. J. Biol. Chem. 278:10374-10380(2003). (3) Kaabeche K. Lemonnier J., et al. J. Biol. Chem. 279:36259-36267(2004). (4) Zhang X. Ibrahimi O.A., et al. J. Biol. Chem. 281:15694-15700(2006). (5) Luo Y. Yang C., et al. Cell. Signal. 21:1370-1378(2009). (6) Cha J.Y. Maddileti S., et al. J. Biol. Chem. 284:6227-6240(2009).
更多信息或购买 :
公司信息
ACROBiosystems
1 Innovation Way Newark, DE 19711, USA
order@acrobiosystems.com
http://www.acrobiosystems.com
1-800-810-0816
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.

Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.

As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.

We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.